Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Moodys
Covington
Healthtrust
Novartis
Farmers Insurance
Cantor Fitzgerald
Fish and Richardson
UBS
Queensland Health

Generated: August 16, 2017

DrugPatentWatch Database Preview

Eagle Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for EAGLE PHARMS, and when can generic versions of EAGLE PHARMS drugs launch?

EAGLE PHARMS has four approved drugs.

There are twenty-one US patents protecting EAGLE PHARMS drugs on EAGLE PHARMS drugs in the past three years. There is one tentative approval on EAGLE PHARMS drugs.

There are eighty-three patent family members on EAGLE PHARMS drugs in thirty-two countries.

Summary for Applicant: Eagle Pharms

Patents:21
Tradenames:4
Ingredients:4
NDAs:4
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eagle Pharms
BENDEKA
bendamustine hydrochloride
SOLUTION;IV (INFUSION)208194-001Dec 7, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Eagle Pharms
BENDEKA
bendamustine hydrochloride
SOLUTION;IV (INFUSION)208194-001Dec 7, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Eagle Pharms
BENDEKA
bendamustine hydrochloride
SOLUTION;IV (INFUSION)208194-001Dec 7, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Eagle Pharms
BENDEKA
bendamustine hydrochloride
SOLUTION;IV (INFUSION)208194-001Dec 7, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Eagle Pharms
BENDEKA
bendamustine hydrochloride
SOLUTION;IV (INFUSION)208194-001Dec 7, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for EAGLE PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
bendamustine hydrochloride
Injection100 mg/4 mL (25 mg/mL) multiple-dose vials
BENDEKA
5/4/2017

Non-Orange Book Patents for Eagle Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,271,964Treatment using dantrolene► Subscribe
8,609,863Bendamustine pharmaceutical compositions► Subscribe
8,436,190Bendamustine pharmaceutical compositions► Subscribe
9,572,888Formulations of bendamustine► Subscribe
8,895,756Bendamustine pharmaceutical compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Eagle Pharms Drugs

Country Document Number Estimated Expiration
Spain2405611► Subscribe
Ukraine94036► Subscribe
Canada2867295► Subscribe
European Patent Office2827862► Subscribe
China104302291► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Eagle Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
172Luxembourg► SubscribePRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
/2013Austria► SubscribePRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317
60002Netherlands► SubscribePRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Cantor Fitzgerald
Fish and Richardson
Julphar
Boehringer Ingelheim
Harvard Business School
Cerilliant
Queensland Health
Dow
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot